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The traditional Chinese medical compound
Rocaglamide protects nonmalignant primary cells
from DNA damage-induced toxicity by inhibition
of p53 expression
MS Becker1, P Schmezer2, R Breuer1, SF Haas3, MA Essers3, PH Krammer1 and M Li-Weber*,1
One of the main obstacles of conventional anticancer therapy is the toxicity of chemotherapeutics to normal tissues. So far,
clinical approaches that aim to specifically reduce chemotherapy-mediated toxicities are rare. Recently, a number of studies
have demonstrated that herbal extracts derived from traditional Chinese medicine (TCM) may reduce chemotherapy-induced
side effects. Thus, we screened a panel of published cancer-inhibiting TCM compounds for their chemoprotective potential and
identified the phytochemical Rocaglamide (Roc-A) as a candidate. We show that Roc-A significantly reduces apoptotic cell death
induced by DNA-damaging anticancer drugs in primary human and murine cells. Investigation of the molecular mechanism of
Roc-A-mediated protection revealed that Roc-A specifically blocks DNA damage-induced upregulation of the transcription factor
p53 by inhibiting its protein synthesis. The essential role of p53 in Roc-A-mediated protection was confirmed by siRNA
knockdown of p53 and by comparison of the effects of Roc-A on chemoprotection of splenocytes isolated from wild-type and
p53-deficient mice. Importantly, Roc-A did not protect p53-deficient or -mutated cancer cells. Our data suggest that Roc-A may be
used as an adjuvant to reduce the side effects of chemotherapy in patients with p53-deficient or -mutated tumors.
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‘Classic’ genotoxic anticancer drugs all target DNA.1 DNA-
damaging agents are potent inducers of cell death by
triggering apoptosis not only in cancer but also in normal
tissues. Especially, the toxicity to the hematopoietic system is
the main challenge in anticancer treatment, as a decrease in
white blood cell counts is usually the dose-limiting factor.2,3
Reduction in leukocytes causes weakening of the immune
system and, thus, often leads to the development of
opportunistic infections that in the worst case can result in
death of the patient.4,5 Nevertheless, induction of DNA
damage, such as DNA double-strand breaks (DSBs), has
been shown to be an effective treatment of cancer.6 In fact,
most currently used anticancer drugs, for example, Etopo-
side, Bleomycin, Doxorubicin, Teniposide and so on, act by
causing DNA damage.6 Taken together, there is an urgent
need for new therapeutic strategies that can reduce the
toxicity of treatment on normal tissues but still maintain
efficacy against the tumor.
Natural products are an important source of drugs in
medicine. Recently, several studies showed that herbal
extracts from traditional Chinese medicine (TCM) could
reduce chemotherapy-induced side effects in vivo.7–10
For instance, the herbal mixture PHY906, which is based on
the TCM Huang Qin Tang, reduced CPT-11-induced toxicity
in mice,10 a finding that is further supported by a phase 1/2
clinical trial.11 Other clinical studies suggest that Chinese
herbal extracts may reduce the chemotherapy-induced
decrease in white blood cell counts.12 These results prompted
us to investigate TCM compounds that could protect normal
tissues from DNA damage-induced cell death.
In this study, we screened a panel of known cancer-
inhibiting TCM compounds for their chemoprotective potential
and found that Rocaglamide (Roc-A) reduces DNA damage-
induced apoptosis in nonmalignant primary cells. Roc-A
belongs to a group of phytochemicals, characterized by a
cyclopenta[b]-tetrahydrobenzofuran backbone, collectively
named rocaglamides that are isolated from the TCM plant
Aglaia.13–15 Roc-A and its derivatives have been shown to
possess anticancer activities in vitro in various tumor cell lines
and patient samples and to inhibit tumor growth in vivo in
several mouse tumor models.14,15 The primary effect of
rocaglamides on tumor growth inhibition was shown to be
caused by inhibition of protein synthesis.16,17 Two mecha-
nisms, which ultimately lead to inactivation of the mRNA
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cap-binding eukaryotic translation initiation factor eIF4E and
the translation initiation factor eIF4A, result in inhibition of
protein synthesis.18,19
We further investigated the molecular mechanisms by
which Roc-A protects normal cells from DNA damage-induced
cell death and revealed that the transcription factor p53 is
essential for this protection. It is well known that p53 plays an
important role in the DNA damage response by inducing the
expression of DNA repair proteins and also of genes involved
in apoptosis, for example, BBC3 (PUMA) and BAX. When
DNA damage exceeds a certain threshold and DNA repair
fails, damaged cells undergo apoptosis.1,20 We show that
Roc-A prevents DNA damage-induced apoptosis in normal
cells by inhibition of p53 expression at the translational level.
Importantly, p53-deficient and mutant tumor cells are not
protected by Roc-A from DNA damage-induced cell death.
Results
Roc-A protects nonmalignant cells against DNA
damage-induced cytotoxicity. To identify TCM com-
pounds that can protect nontransformed primary cells from
DNA damage-induced cytotoxicity, we performed a cell
viability screen. Human peripheral blood T lymphocytes
(T cells) from healthy donors were used as a model cell for
healthy tissue. T cells were treated with the genotoxic
chemotherapeutic drug Etoposide in the absence or pre-
sence of different TCM compounds. After 24 h of treatment,
cell viability was determined by the Cell-Titer Glo viability
assay (Promega, Mannheim, Germany). Among the
analyzed compounds, Roc-A showed the strongest chemo-
protective effect on T cells by reducing Etoposide-induced
cytotoxicity by more than twofold (Figure 1a). Therefore, we
focused on Roc-A for further analysis.
To validate the screening results, we treated normal T cells
with increasing concentrations of Etoposide with or without
different concentrations of Roc-A. After 24 h of treatment,
apoptotic cell death was measured by specific DNA fragmen-
tation, AnnexinV staining or determination of apoptotic-like
changes in cell size and cellular granularity (FSC/SSC profile).
The experiments showed that Etoposide treatment caused
cell death of normal T cells that was reduced in the presence
of Roc-A in a dose-dependent manner to 450% (Figure 1b,
left panel and Supplementary Figure S1). Kinetic analysis
showed that Roc-A could reduce the toxicity of Etoposide at all
measured time points (Figure 1b, middle panel). Strikingly, the
chemoprotective effect could be even seen when Roc-A was
administered after several hours of Etoposide treatment
(Figure 1b, right panel).
To investigate whether Roc-A could also protect normal
cells from cell death induced by other DNA damaging
anticancer drugs, we treated T cells with increasing doses of
Teniposide, Doxorubicin and Bleomycin in the presence or
absence of Roc-A. The experiment showed that Roc-A could
reduce drug-induced apoptosis in all cases (Figure 1c).
Next, we asked whether Roc-A could also protect other
normal primary cells from DNA damage-induced toxicity.
To address this question, we examined the protective effect of
Roc-A on Etoposide-treated human peripheral blood
B cells, NK cells, neutrophils, cardiomyocytes and murine
hematopoietic stem and progenitor cells (HSPCs). The
experiments revealed that all examined cells were protected
by Roc-A against Etoposide-induced apoptosis (Figure 1d).
Taken together, these data indicate that Roc-A can protect
primary nonmalignant cells from DNA damage-induced
cytotoxicity.
Roc-A exerts its protection downstream of DNA damage.
Genotoxins such as Etoposide induce apoptosis mainly
through induction of DNA damage.21 We therefore asked
whether Roc-A could prevent genotoxin-induced DNA
damage and thereby reduces genotoxin-induced cell death.
To address this question, we determined the level of the
DNA-damage marker g-H2AX that is generated around the
site of a DNA DSB.22 Etoposide treatment resulted in an
increase in g-H2AX foci formation in a concentration- and
time-dependent manner (Figures 2a and b). A maximum
amount of g-H2AX foci formation was observed at 4 h after
treatment (Figure 2b). However, Roc-A did not block Etopo-
side-induced g-H2AX foci formation (Figures 2a–c). Similar
results were obtained by alkaline single-cell gel electrophor-
esis assay (Comet assay) that detects both DNA
single-strand breaks (SSBs) and DSBs (Figure 2d and e).
Therefore, the protective effect of Roc-A appears to be
downstream of DNA damage.
Roc-A inhibits DNA damage-induced increase in p53
expression. The transcription factor p53 is a major regulator
of DNA damage-induced apoptosis.23 Therefore, we inves-
tigated the effect of Roc-A on the expression level of p53.
T cells were treated with increasing concentrations of Etopo-
side in the presence or absence of Roc-A and p53 protein
expression was analyzed by immunoblot. The experiment
showed that Etoposide treatment increased p53 protein levels.
However, in the presence of Roc-A, p53 expression was
blocked in a dose-dependent manner (Figure 3a).
Roc-A-mediated suppression of p53 upregulation was not
specific for Etoposide, as inhibition was also observed in
Bleomycin-, Teniposide- and Doxorubicin-treated cells
(Figure 3b). Kinetic analysis showed that the increase in p53
protein levels could be detected as early as 4 h after
Etoposide treatment and reached the highest level at 24 h
(Figure 3c and Supplementary Figure S2). Roc-A could inhibit
upregulation of p53 at all time points analyzed (Figure 3c). The
time of p53 upregulation coincided with the onset of apoptosis
induction (Figure 1b). To ensure that Roc-A-mediated
suppression of p53 upregulation was not only specific for
T cells, the effect of Roc-A on p53 expression was also
examined in B and NK cells treated with Etoposide. Consistent
with the results obtained for T cells, Etoposide-induced p53
increase in B and NK cells was also suppressed by Roc-A
(Figures 3d and e). These data indicate that Roc-A
might protect normal tissue from DNA damage-induced
apoptosis by downregulation of genotoxin-induced p53
expression.
p53 plays an essential role in Roc-A-mediated protection.
To investigate the role of p53 in Roc-A-mediated protection
of normal tissue, we induced p53 upregulation without the
induction of DNA damage. To do so, T cells were treated with
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Nutlin-3 which has been shown to increase p53 protein levels
by preventing Mdm2-mediated p53 degradation.24 This
experiment showed that Roc-A could also inhibit Nutlin-3-
induced p53 upregulation and, consequently, cell death
(Figure 4a). Thus, Roc-A does not solely affect DNA
damage-induced cell death, but may in general affect p53-
mediated cell death. This assumption was supported by
analysis of p53 target genes that are involved in apoptosis
regulation. For instance, Etoposide-induced increase in BAX,
MDM2, BBC3 (PUMA) and FAS mRNA expression was
blocked in the presence of Roc-A (Figure 4b). As a control,
the mRNA level of BCL2L11 (BIM), whose expression is not
regulated by p53,25 was shown not to be considerably
affected by Roc-A (Figure 4b).
To further investigate the role of p53 in Roc-A-mediated
protection of T cells against DNA damage-induced apoptosis,
we performed a p53-knockdown experiment using two
siRNAs directed against p53 which yielded similar results
(Figure 4c, upper panel, data are only shown for one siRNA).
The experiment showed that downregulation of p53 protein
levels in T cells (Figure 4c, upper panel, lane 7) rendered the
cells more resistant to Etoposide and reduced cell death to a
level similar to Roc-A treatment (Figure 4c, lower panel).
As the siRNA-mediated p53 knockdown could not fully block
p53 expression (Figure 4c, upper panel, lane 7), Roc-A could
still further downregulate the expression of p53 in
p53-knockdown cells (Figure 4c, upper panel, lane 8).
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Figure 1 Roc-A protects nonmalignant cells from DNA damage-induced cytotoxicity. (a) A cell viability screen reveals Roc-A to be a potential DNA damage-protective
compound. Peripheral blood T cells from healthy donors were treated with solvent (DMSO) or 50 mM Etoposide in the presence of different TCM compounds or solvent as
indicated. Cell viability was determined after 24 h of treatment by Cell-Titer Glo viability assay. Data are an average of three independent experiments. (b) Roc-A protects
T cells from Etoposide-induced cell death in a dose- and time-dependent manner. Left panel: T cells were treated with solvent (DMSO) or increasing amounts of Etoposide in
the presence of different concentrations of Roc-A or solvent (DMSO) for 24 h. Cell death was determined by DNA fragmentation. Data are an average of three independent
experiments. Error bars (S.D.) are shown. Middle panel: T cells were treated with 50 mM Etoposide in the presence of different concentrations of Roc-A or solvent (DMSO) for
the indicated time periods. Cell death was determined by DNA fragmentation. Data are an average of three independent experiments. Error bars (S.E.M.) are shown. Right
panel: Roc-A was added 2 h before, in parallel or 2 and 4.5 h after Etoposide (50 mM) treatment. Data are presented as percent of protection of
T cells from Etoposide-induced cell death. Results are an average of three independent experiments. Error bars (S.E.M.) are shown. (c) Roc-A reduces Teniposide-,
Doxorubicin- and Bleomycin-induced cell death in T cells. Peripheral blood T cells were treated with Teniposide (left panel), Doxorubicin (middle panel), Bleomycin (right panel)
or solvent (DMSO) in the presence of Roc-A (75 nM) or solvent (DMSO) as indicated. Cell death was determined by DNA fragmentation for Teniposide and Bleomycin
treatment or by FSC/SSC profile for Doxorubicin treatment. Data are an average of three independent experiments. Error bars (S.D.) are shown. (d) Roc-A protects a panel of
nontransformed primary cells from Etoposide-induced cell death. Primary human B cells, NK cells, neutrophils, HSPCs and cardiomyocytes were treated with solvent (DMSO)
or Etoposide in the presence of different concentrations of Roc-A or solvent (DMSO) for different times as indicated. Cell death was determined by DNA fragmentation. Results
are an average of three to four independent experiments. Error bars (S.D.) are shown
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cells from Etoposide-induced apoptosis (Figure 4c, lower
panel). As siRNA-mediated knockdown of p53 could not
fully block p53 expression, we examined the effect of Roc-A
on p53 knockout (KO) cells. Splenocytes derived from wild-
type (WT) and p53-KO mice were treated with Etoposide in
the presence or absence of Roc-A. In line with the data
observed in primary human cells, Roc-A protected spleno-
cytes derived from p53-WT but not from p53-KO animals
against Etoposide-induced cell death (Figure 4d). These
results demonstrate that p53 plays an essential role in Roc-A-
mediated chemoprotection.
Roc-A does not protect malignant cells with non-
functional p53. As Roc-A-mediated protection of nonmalig-
nant cells from DNA damage-induced cell death is largely p53
dependent, we predicted that Roc-A may protect cancer cells
having functional p53 but would not protect cancer cells
having nonfunctional p53. As expected, Roc-A neither
protected p53-mutated (L1236,26 Hut-78,27 DND-4128 and
SCLC-21H29) nor p53-deficient (HL-6029) cancer cell lines
against Etoposide-induced cell death (Figure 5a). We then
further tested cancer cell lines EU-3,30 IM-9,31 Reh,30
SKW6.432 and NCI-H20933 that have a WT p53 protein. The
experiments showed that EU-3, SKW6.4 and IM-9 cells were
protected by Roc-A from Etoposide-induced cell death but to a
lesser extent than nonmalignant cells (Figure 5b and
Supplementary Figure S3). Thus, Roc-A may also protect
some p53-WT tumors from DNA-damaging drugs.
Roc-A suppresses p53 upregulation via inhibition of
protein synthesis. The protein expression of p53 can be
regulated at the level of transcription, translation and
ubiquitination-mediated degradation.34 It has been shown that
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Figure 2 Roc-A does not protect T cells from genotoxin-induced DNA damage. (a) Roc-A does not prevent Etoposide-induced increase in g-H2AX. T cells were treated
with solvent (DMSO) or different concentrations of Etoposide in the presence of Roc-A (75 nM) or solvent (DMSO) for 4 h. DSB induction was assessed by determination of the
mean fluorescence intensity (MFI) of g-H2AX-stained cells. Data are an average of three independent experiments. Error bars (S.D.) are shown. (b) Kinetic analysis of the
effect of Roc-A on Etoposide-induced DSBs. T cells were treated with 50 mM Etoposide in the presence of Roc-A (75 nM) or solvent (DMSO) for different times and DSB
induction was determined as described in (a). Data are an average of three independent experiments. Error bars (S.D.) are shown. (c) Confocal microscopy analysis of
Etoposide-induced g-H2AX-foci in the absence or presence of Roc-A. Nuclei of cells, obtained from (a) and (b), were stained with DAPI (blue) and imaged by confocal
microscopy. g-H2AX staining is shown in green. Three representative nuclei are shown for each treatment. (d) Comet assay to monitor the effect of Roc-A on Etoposide-
induced DNA damage in T cells. Peripheral blood T cells were treated with solvent (DMSO) or Etoposide (50 mM) in the presence of Roc-A (75 nM) or solvent (DMSO) for
different time periods as indicated. A comet assay was carried out subsequently. The distribution of olive tail moments (OTM) among treated cells is shown. Data are
representative of three different healthy donors. (e) Summary of the data obtained from (d). Results are an average of the mean OTM of three different healthy donors. Error
bars (S.D.) are shown. *Po0.05, calculated by the unpaired Student’s t-test with Welch’s correction
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modifications leading to its deubiquitination and, thus,
stabilization.35 To investigate whether Roc-A could decrease
p53 stability, we treated T cells with the proteasome inhibitor
Bortezomib to block proteasome-mediated degradation.
Bortezomib treatment led to an increase in p53 in the absence
of Roc-A (Figure 6a). However, Bortezomib could not increase
p53 in the presence of Roc-A and also did not interfere with
the ability of Roc-A to block Etoposide-induced p53 upregula-
tion (Figure 6a). To further investigate the effect of Roc-A on
p53 stability, the status of p53 ubiquitination was analyzed
after Etoposide treatment in the absence or presence of Roc-A.
Etoposide treatment led to a decrease in p53 ubiquitination.
However, Roc-A had no effect on p53 ubiquitination
(Figure 6b). These results demonstrate that Roc-A is unlikely
to suppress p53 upregulation through decreasing p53 stability.
In addition, p53 has been shown to be upregulated at the
translational level following DNA damage.36,37 Roc-A has
been well documented to inhibit protein translation.18,19,38,39
Thus, we hypothesized that Roc-A-mediated suppression of
genotoxin-induced p53 upregulation may be caused by
inhibition of p53 protein synthesis. To test this, we examined
the effects of different Roc-A derivatives that have been
shown to exert different activities on inhibition of ERK-
mediated protein synthesis.18 By means of [35S]methionine
incorporation analysis, Roc-A, -AB, -J, -AR and -Q, which
have been shown to inhibit ERK activation with different
efficacies,18 inhibited [35S]methionine incorporation at different
degrees that correlated with different levels of protection of
normal T cells from Etoposide-induced cell death (Figure 6c).
In contrast, Roc-AA, -AF and -I, which do not show any or very
little inhibitory effect on ERK activity,18 did not inhibit protein
translation and did not protect T cells against Etoposide-
induced cytotoxicity (Figure 6c).
To confirm that Roc-A inhibits p53 protein synthesis, we
carried out a [35S]methionine-metabolic pulse-labeling experi-
ment and then immunoprecipitated p53 after Etoposide
treatment. The experiment showed that Roc-A suppressed
[35S]methionine incorporation into the p53 protein (Figure 6d).
To further exclude that Roc-A influences p53 expression at
the transcriptional level, we examined p53 mRNA expression
levels upon Etoposide treatment in the presence of Roc-A or
solvent (DMSO) by quantitative real-time PCR. The experi-
ment showed that Roc-A does not reduce p53 mRNA
expression in Etoposide-treated cells (Figure 6e). Thus,
Roc-A suppresses DNA damage-induced upregulation of
p53 at the translational level.
Discussion
Chemotherapy is broadly used among current standard
treatment modalities for cancer patients, in particular for
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Figure 3 Roc-A blocks genotoxin-induced upregulation of p53. (a and b) Roc-A inhibits Etoposide- (a), Bleomycin-, Teniposide- and Doxorubicin (b)-induced p53
upregulation in T cells. T cells were treated with solvent or different anticancer drugs in the presence of different concentrations of Roc-A or solvent (DMSO) as indicated.
Cell lysates were subjected to immunoblot analysis with antibodies against p53. Actin or tubulin were used as loading controls. Data are representative of three independent
experiments. (c) Kinetic analysis of the effect of Roc-A on Etoposide-induced p53 upregulation. T cells were treated with solvent (DMSO) or 50 mM Etoposide in the presence
of 75 nM Roc-A or solvent (DMSO) for different time periods as indicated. Cell lysates were subjected to immunoblot analysis with antibodies against p53 and tubulin. Data are
representative of two independent experiments. (d and e) Roc-A inhibits Etoposide-induced p53 upregulation in B cells (d) and NK cells (e). Cells were treated with solvent
(DMSO) or Etoposide in the presence of Roc-A or solvent (DMSO) as indicated and cell lysates were subjected to immunoblot analysis. Data are representative of two
independent experiments. In (a, b, d), the double band observed for p53 is likely to occur because of a heterozygous p53 R72P polymorphism
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anticancer drugs are genotoxins that induce DNA damage.
This therapy has a major drawback of causing severe side
effects. Because of these side effects, dosages have to be
reduced or the treatment has to be discontinued completely.
In this study we show that the TCM compound Roc-A can
reduce DNA-damaging drug-induced cytotoxicity in human
and murine primary cells. The protective effect of Roc-A is not
limited to a certain cell type or a specific DNA-damaging agent
(Figure 1). Thus, our data strongly suggest a potential use of
Roc-A as a chemoprotective agent.
Investigation of the molecular mechanisms by which Roc-A
protects normal cells from chemotherapy-induced cytotoxicity
revealed that p53 is a key factor in Roc-A-mediated
protection. We show that Roc-A does not reduce genotoxin-
induced DNA damage (Figure 2), but inhibits genotoxin-
induced upregulation of p53 in different primary cells
(Figure 3). The essential role of p53 in Roc-A-mediated
protection is evidenced by the following: (1) upregulation of
p53 by Nutlin-3 (without inducing DNA damage) could be
suppressed by Roc-A and downregulation of p53 coincided
with reduced cell death in Nutlin-3-treated normal T cells
(Figure 4a); (2) suppression of p53 expression by Roc-A
coincided with downregulation of Etoposide-induced p53-
target genes, such as BAX, MDM2, BBC3 (PUMA) and FAS
in normal T cells (Figure 4b); (3) siRNA-mediated knockdown
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Figure 4 Roc-A-mediated chemoprotection depends on p53. (a) Roc-A inhibits Nutlin-3-induced p53 upregulation and protects T cells from Nutlin-3-induced cell death. T cells
were treated with solvent (DMSO) or Nutlin-3 in the presence of Roc-A or solvent (DMSO) as indicated. After 24 h of treatment, the expression levels of p53 were analyzed by
immunoblot (upper panel). Cell death was determined after 48 h of treatment by FSC/SSC profile (lower panel). Data are representative of three independent experiments. Error
bars (S.D.) are shown. (b) Roc-A reduces Etoposide-induced mRNA expression of p53 target genes. T cells were treated with solvent (DMSO) or Etoposide (50mM) in the
presence of Roc-A (75 nM) or solvent (DMSO) for different time periods as indicated. Total RNA was isolated and subjected to quantitative real-time PCR for BAX,MDM2, BBC3
(PUMA), FAS and BCL2L11 (BIM). Data are presented as fold change in mRNA levels and normalized to control treatment with solvent (DMSO). Data are representative of three
independent experiments. Error bars (minimum and maximum) are shown. (c) siRNA-mediated knockdown of p53 mimics the protective effect of Roc-A. T cells were transfected
with scrambled (si-Ctrl.) or specific siRNA targeting p53 (si-p53). At 24 h after transfection, T cells were treated with solvent (DMSO) or Etoposide (50mM) in the presence of Roc-A
(75 nM) or solvent (DMSO) as indicated for 24 h. The expression levels of p53 were analyzed by immunoblot and cell death was determined by FSC/SSC profile. Data are
representative of three independent experiments. Error bars (S.D.) are shown. (d) Roc-A-mediated protection is abolished in p53 / splenocytes. Splenocytes from p53 / or
p53þ /þ mice were treated with 50mMEtoposide in the presence of 75 nMRoc-A or solvent (DMSO) for indicated time periods. Cell death was determined by DNA fragmentation.
Data are an average of four independent experiments. Error bars (S.D.) are shown
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Roc-A treatment and resulted in a similar level of protection of
T cells from Etoposide-induced cell death (Figure 4c); and (4)
p53-WT but not p53-KO splenocytes were protected by Roc-A
from Etoposide-induced cell death (Figure 4d). These data
are consistent with the fact that p53 is involved in DNA
damage-induced apoptosis23,40 and that decreased p53
protein levels confer resistance to a large number of DNA-
damaging chemotherapeutics in vitro23,40 and in vivo.41
Approximately 50% of all known cancers are either deficient
for p53 or carry a mutation in p53 that abolishes p53-WT
function.42 We show that Roc-A does not protect Etoposide-
treated tumor cell lines that either contain p53 mutations
(L1236,26 Hut-78,27 DND-4128 and SCLC-21H29) or that are
p53-deficient (HL-6029) (Figure 5a). These results indicate that
Roc-A may be used to reduce the side effects of chemotherapy
in the treatment of p53-deficient or -mutated cancers. As p53
plays a decisive role in Roc-A-mediated protection, one can
presume that Roc-A may protect p53-WT tumors against
genotoxin-induced cell death. As predicted, Roc-A was shown
to indeed reduce Etoposide-induced cell death in several p53-
WT tumor cell lines including EU-3 acute lymphoblastic
leukemia cells, SKW6.4 leukemic B cells and IM-9 chronic
myeloid leukemia cells (Figure 5b). However, the protective
effect of Roc-A on p53-WT tumor cells was less efficient
compared with nonmalignant cells (Figure 1 and
Supplementary Figure S3). Intriguingly, some p53-WT tumor
cells, for example, the acute lymphoblastic leukemia cell line
Reh and the small cell lung cancer cell line NCI-H209, were not
protected by Roc-A (Figure 5b). This result may be explained
by mutations of genes in the p53 signaling pathway that often
occur in p53-WT cancers.42,43 In addition, Roc-A has been
shown to have a much higher cytotoxicity on cancer than on
nonmalignant cells by differential regulation of activities of
mitogen-activated protein kinases.44 Furthermore, Roc-A has
been shown to inhibit the Ras/CRaf/MEK/ERK signaling
pathway that is one of the key signaling pathways regulating
tumor survival.18,45
In this study, we also investigated the molecular mecha-
nism by which Roc-A inhibits DNA damage-induced p53
upregulation. Under unstressed conditions, p53 is negatively
regulated by Mdm2 that binds to and inhibits p53 activity and
leads to its degradation by the ubiquitination-mediated
proteasomal pathway.46 Genotoxic stress has been shown
to inhibit Mdm2-mediated p53 degradation and increase the
stability and, consequently, protein levels of p53.35 Our
experiments showed that Roc-A neither alters the basal level
of p53 ubiquitination nor the level of p53 ubiquitination upon
Etoposide treatment (Figure 6b). Moreover, blocking protea-
somal activity did not lead to a reduction in Roc-A-mediated
suppression of p53 upregulation (Figure 6a). Thus, we
conclude that Roc-A does not affect p53 stability. Genotoxic
stress can also increase the expression of p53 at the
translational level.36,37 Roc-A and its derivatives are potent
inhibitors of protein synthesis.14,15,18,19,38 Indeed, Roc-A and
its active derivatives Roc-AB, J, AR and Q,18 but not the
inactive derivatives Roc-AA, AF and I,18 were shown to inhibit
Etoposide-induced protein translation (Figure 6c). The degree
of translation inhibition correlated with the efficacy of
chemoprotection by Roc-A and its derivatives (Figure 6c).
Moreover, Roc-A was shown to inhibit p53 translation
(Figure 6d). Furthermore, Roc-A did not reduce the mRNA
levels of p53 (Figure 6e). These data demonstrate that Roc-A
inhibits DNA damage-induced upregulation of p53 by inhibi-
tion of protein synthesis.
















































































































































































































































L1236 Hut-78 DND-41 SCLC-21H HL-60
EU-3 IM-9 SKW 6.4 NCI-H209 Reh
DMSO Roc-A 12.5 nM Roc-A 25 nM Roc-A 75 nMRoc-A 50 nM
DMSO Roc-A 12.5 nM Roc-A 25 nM Roc-A 75 nMRoc-A 50 nM
Figure 5 Roc-A does not protect cancer cell lines with nonfunctional p53. p53-mutated or -deficient cancer cell lines (a) and p53 WT cell lines (b) were treated with solvent
(DMSO) or different concentrations of Etoposide in the presence of increasing amounts of Roc-A or solvent (DMSO) as indicated. Cell death was determined by DNA
fragmentation after 24 or 48 h of treatment as indicated. Results are averages of three independent experiments. Error bars (S.D.) are shown
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p53 is a well-known tumor suppressor. Thus, blocking p53
expression might increase the risk of tumor development.
However, a number of studies show that transient pharma-
cological or genetic inactivation of p53 before or after
genotoxic stress does not lead to increased carcinogenesis.47–49
Moreover, recent publications indicate that the tumor-sup-
pressor function of p53 is independent from its functions on
apoptosis and cell cycle.50,51
In this study, we also show that, in principle, all bioactive
derivatives of Roc-A may protect normal cells from genotoxin-
induced cytotoxicity (Figure 6c). In line with our studies,
several compounds belonging to the same structural family of
Roc-A were recently shown to protect rat and murine
cardiomyocytes against doxorubicin-induced apoptosis.52,53
Doxorubicin is also a DNA-damaging anticancer drug. There-
fore, cardioprotection by these compounds may also involve
p53. Moreover, p53 has been implicated in certain neurological
disorders, such as Alzheimer’s and Parkinson’s disease.54,55
Interestingly, some structural-related compounds of Roc-A
were shown to have neuroprotective effects in vitro on neuron
cells and in vivo in animal models of Parkinson’s disease and
stroke.53,56 In this regard, our results may offer a potential
mechanism for the neuroprotective action of these
compounds.
Taken together, our data demonstrate that Roc-A selec-
tively protects nonmalignant human primary cells against
DNA damage-induced apoptosis via a p53-dependent
mechanism. Thus, Roc-A and its derivatives may be attractive
compounds for the treatment of side effects of current
chemotherapy.
Materials and Methods
Reagents and Roc derivatives. Etoposide (Biotrend Chemikalien GmbH,
Cologne, Germany), Bleomycin (sulfate) (Cayman Chemical Company, Ann Arbor,
MI, USA), Doxorubicin (Sigma-Aldrich, Munich, Germany), Nutlin-3 (Sigma-Aldrich)
and Teniposide (Enzo Life Sciences, Lörrach, Germany) were used for apoptosis















































































1 2 3 4 5 6 7





















Figure 6 Roc-A inhibits upregulation of p53 via inhibition of protein synthesis. (a) Inhibition of proteasome-mediated degradation does not influence Roc-A-mediated
chemoprotection. T cells were treated with solvent (DMSO) or 100 nM Bortezomib to block proteasome-mediated protein degradation and treated with solvent (DMSO) or
50mM Etoposide in the presence of 75 nM Roc-A or solvent (DMSO) for 4 h. Cell lysates were subjected to immunoblot analysis with antibodies against p53 and Actin. Data
are representative of three independent experiments. (b) Roc-A does not influence ubiquitination of p53. T cells were treated with Bortezomib, Etoposide and Roc-A as in (a).
After 4 h of treatment, cell lysates were used for immunoprecipitation against p53. Isotype-matched antibody-coupled beads and uncoupled beads were used as controls.
Ubiquitinated p53 ((UB)n-p53) is indicated. Data are representative of two independent experiments. (c) Inhibition of protein translation by Roc-A or its derivatives correlates
with their chemoprotective effects. Effects of Roc-A and its derivatives (-AB, -J, -AR, -Q, -I, -AF and -AA) on protein synthesis in T cells was determined by measuring the
amounts of incorporation of [35S]-labeled methionine. Cell death was determined by DNA fragmentation of T cells treated with solvent (DMSO) or 50 mM Etoposide in the
presence of 75 nM of different Roc-derivatives or solvent (DMSO) for 24 h. The percentage of chemoprotection was determined by calculating the percentage of protection
against Etoposide-induced cell death. The data are shown by plotting the percentage of translation inhibition against the percentage of chemoprotection. Data are an average
of three independent experiments. Error bars (S.E.M.) are shown. An allosteric sigmoidal regression curve was plotted against the experimental data. R2¼ 0.96. (d) Roc-A
inhibits p53 protein translation. T cells were treated according to (a), followed by metabolic pulse-labeling for indicated time periods and immunoprecipitation. Data are
representative of three independent experiments. (e) Roc-A does not reduce the mRNA levels of p53. T cells were treated with solvent (DMSO) or 50 mM Etoposide in the
presence of 75 nM Roc-A or solvent (DMSO) for indicated time periods. Total RNA was isolated and was subjected to quantitative real-time PCR for TP53. Data are presented
as fold increase in mRNA levels determined by comparison of HPRT1 gene expression levels with TP53 and normalized to control treatment with solvent (DMSO). Data are an
average of three independent experiments. Error bars (S.D.) are shown
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induction. Roc-A (498% pure; Enzo Life Sciences) and derivatives
Roc-AA (C-1-O-acetyl-methylrocaglate), Roc-AB (1-O-acetyl-rocaglamide), Roc-AF
(30,40-methylendioxy-methylro-caglate), Roc-AR (1-oxo-40-demethoxy-30,40-methyle-
nedioxyrocaglaol), Roc-I (C-1-O-acetyl-30-hydroxy-rocaglamide), Roc-J (30-hydroxya-
glafoline) and Roc-Q (demethylrocaglamide) were isolated from Aglaia species to the
purity of 498% as determined by high-performance liquid chromatography (HPLC).
Primary human cells and cell cultures. The human malignant cell lines
EU-3 (acute lymphoblastic leukemia), DND-41 (T-cell leukemia), Hut-78 (T-cell
lymphoma), SKW6.4 (B-cell leukemia), Reh (acute lymphoblastic leukemia), IM-9
(chronic myeloid leukemia), HL-60 (promyelocytic leukemia), L1236 (Hodgkin’s
lymphoma) and NCI-H209 (small cell lung cancer) were cultured at 371C with 5%
CO2 in RPMI-1640 medium (Sigma-Aldrich) supplemented with 10% FCS, 100 U/ml
Penicillin (Sigma-Aldrich) and 100mg/ml Streptamycin (Sigma-Aldrich). SCLC-21H
cells (small cell lung cancer) were cultured in DMEM medium (Sigma-Aldrich)
supplemented with 10% FCS. Peripheral blood T lymphocytes were isolated as
previously described.57 B lymphocytes and NK cells were isolated by magnetic-
activated cell sorting using ‘B cell isolation kit II’ (Miltenyi Biotech, Bergisch
Gladbach, Germany) and ‘NK cell isolation kit, human’ (Miltenyi Biotech),
respectively, according to the manufacturer’s instructions. Human neutrophils were
separated from peripheral blood mononuclear cells by Ficoll-Paque density
centrifugation, followed by incubation in 1.05% dextran for 30min at room
temperature. Remaining erythrocytes were lysed by resuspension in ice-cold 0.2%
sodium chloride solution. After 1min, ice-cold 1.6% sodium-chloride solution was
added and lysis was stopped by addition of PBS and neutrophils were
resuspended in medium at a concentration of 2 106 cells/ml. Human primary
cardiomyocytes were purchased from PromoCell (Heidelberg, Germany) and
cultured in myocyte growth medium (PromoCell). Remaining primary human cells
were cultured in RPMI-1640 medium with the same conditions described above.
Cell viability screen. Human peripheral blood T lymphocytes were treated
for 24 h with the following compounds: Atropine (VWR International, Darmstadt,
Germany), Artemisinin (MP Biomedicals, Eschwege, Germany), Embelin (Sigma-
Aldrich), Rocaglamide, Camphor (MP Biomedicals), Caffeine (Sigma-Aldrich),
Luteolin (Sigma-Aldrich), Curcumin (Alexis Biochemicals, San Diego, CA, USA),
Wogonin (Wako Pure Chemical Industries, Osaka, Japan), b-Escin (MP
Biomedicals), Berberine (Biomol, Hamburg, Germany), Triptolide (Enzo Life
Sciences), Chrysin (Sigma-Aldrich), Baicalein (Biomol), Resveratrol (MP
Biomedicals), Quercetin (Sigma-Aldrich), Emodin (Biotrend Chemikalien GmbH),
Baicalin (Sigma-Aldrich) and Coumarin (Fisher Scientific, Schwerte, Germany).
Cell viability was determined by the Cell-Titer Glo assay (Promega) according to
the manufacturer’s instructions.
Apoptosis measurements. Apoptotic cell death was determined by
AnnexinV staining, cellular forward scatter/side scatter (FSC/SSC) profile or
DNA fragmentation. For AnnexinV staining, 2 105 cells were treated with
different drugs for indicated time periods, washed with AnnexinV binding buffer
(0.01M Hepes, 0.14 M NaCl, 2.5 mM CaCl2), and stained with AnnexinV–FITC
antibody (Immunotools, Friesoythe, Germany) and 7-amino-actinomycin D (Sigma-
Aldrich) for 30min at 41C. The amount of AnnexinV-positive cells was determined
by FACS measurement. DNA fragmentation was determined according to the
method of Nicoletti et al.58 Briefly, 2 105 cells were treated as indicated, washed
with PBS and lysed in Nicoletti buffer (0.1% sodium citrate, 0.1% Triton X-100,
50mg/ml propidium iodide). DNA fragmentation was determined by FACS.
Apoptotic-like cells were determined by FSC/SSC index. Specific DNA
fragmentation/specific AnnexinV-positive cells/specific cell death was calculated
as follows: (percentage of experimental DNA fragmentation (or AnnexinV-positive
cells or cell death) percentage of spontaneous DNA fragmentation (or
AnnexinV-positive cells or cell death)/(100 percentage of spontaneous DNA
fragmentation (or AnnexinV-positive cells or cell death)) 100.
Immunoblot analysis. Immunoblot analysis was carried out as previously
described.18 Briefly, 4–20 106 cells were treated with different reagents as
indicated and lysed in RIPA buffer (50mM Tris HCl, 137mM NaCl, 0.5% Na
Deoxycholate, 1% Triton X-100, 0.1% SDS, protease inhibitors). Proteins were
separated by SDS-PAGE and transferred to a nitrocellulose membrane
(Amersham Biosciences, Little Chalfon, UK) using a semi-dry blotting approach.
The following antibodies were used: p53 (DO-1) antibody was purchased from
Santa Cruz Biotechnology (Heidelberg, Germany). Tubulin and actin (A5441)
antibodies were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Immunoprecipitation and metabolic pulse-labeling experiments.
For immunoprecipitation, cells were treated for 4 h with Etoposide and/or Roc-A in
the absence or presence of 100 nM Bortezomib (Enzo Life Sciences). In the case
of metabolic pulse-labeling experiments, treatment was followed by adding
100mCi/ml of [35S]-methionine-labeling mix (PerkinElmer, Waltham, MA, USA) to
the medium for 0–15min. Subsequently, cells were washed in ice-cold PBS, lysed
in IP buffer (20mM Tris-HCl, 5 M NaCl, 2 mM EDTA, 1% Triton X-100, protease
inhibitors) and centrifuged (10 000 g, 20 min) to clear lysates. Aliquots were
taken for input control and lysates were incubated overnight with sepharose-
coupled protein A beads, anti-p53 antibody (FL-393; Santa Cruz) or isotype control
antibody (Sigma-Aldrich). Two wash steps with IP buffer preceded boiling of beads
in denaturing sample buffer at 951C for 5 min. Incorporation of [35S]-methionine
into p53 protein was detected by the phosphoimaging system FLA-7000 IR
(Fujifilm Europe GmbH, Düsseldorf, Germany).
Translation assay. The relative amount of protein synthesis was determined
by measuring the amount of incorporation of [35S]-methionine into the protein.
Briefly, cells were precultured in methionine-free medium (supplemented with 10%
dialyzed FCS) for 3 h, followed by incubation with 3.5mCi of [35S]-methionine-
labeling mix (PerkinElmer) per 8 105 cells for 6 h as indicated. After the
treatment, cells were washed twice with ice-cold PBS and lysed in RIPA buffer.
Then, 50ml of each lysate was added to 1ml of Liquid Scintillation Cocktail
solution (Beckman Coulter, Brea, CA, USA) and the amount of incorporated
radioactivity was determined by liquid scintillation counting.
Isolation of primary murine splenocytes. P53 / C57Bl/6 mice
(B6.Trp53tm1Tyj) were kindly provided by Liu H-K (German Cancer Research
Center, Heidelberg, Germany). Spleens of 8–12-week-old p53 / and p53þ /þ
mice were isolated in parallel, minced and incubated for 30min in RPMI-1640
medium supplemented with DNase I (50 U/ml) and Collagenase IV (1mg/ml) at
371C and 5% CO2. Splenocytes were filtered by 40mM cell strainer, washed twice
with ice-cold wash buffer (PBS, 0.5% FCS, 2 mM EDTA) and resuspended in
Oxford medium (RPMI-1640, 10% FCS, 100mg/ml penicillin, 100 mg/ml
streptamycin, 10mM Hepes, 50mM b-mercaptoethanol, 2 mM L-glutamine,
1 mM sodium pyruvate, 100mM nonessential amino acids) at a concentration of
2 106 cells/ml.
Enrichment of HSPCs by lineage depletion. For enrichment of
HSPCs, 8-week-old C57Bl/6 wild-type mice (Harlan Laboratories, Rodorf,
Germany) were killed and bone marrow was prepared from hind legs (femur and
tibia), fore legs (humerus), hips (ilium) and vertebral column (columna vertebralis)
by crushing bones in RPMI-1640 medium (Sigma-Aldrich) supplemented with 2%
FCS. To perform lineage depletion, bone marrow cells were incubated on ice for
40min with rat monoclonal antibodies against common epitopes expressed on
mature blood and bone marrow cells (CD11b (M1/70), Gr-1 (RB6.8C5), CD4
(GK1.5), CD8a (53.6.7), Ter119 (Ter119) and B220 (RA3-6B2)). Subsequently,
cells were washed and incubated for 15min on ice with anti-rat IgG-coated
Dynabeads (4.5mm supermagnetic polystyrene beads, Invitrogen, Darmstadt,
Germany), 1 ml of beads per 3 108 bone marrow cells. Cells expressing lineage
markers were depleted using a magnet and the remaining lineage-negative cells
were isolated and washed. To provide optimal conditions for HSPCs in
downstream experiments, lineage-negative hematopoietic stem and progenitor-
enriched cells were cultured in StemPro-34 serum-free medium (Invitrogen)
supplemented with nutrient supplement (Invitrogen) as well as recombinant TPO
(50 ng/ml; Peprotech, Hamburg, Germany), SCF (50 ng/ml; Peprotech) and Flt3
ligand (50 ng/ml; Peprotech).
Knockdown experiments. The siRNAs specific for p53 mRNA are
(50-GGUGAACCUUAGUACCUAAtt-30 or 50-GUAAUCUACUGGGACGGAAtt-30;
Applied Biosystems, Darmstadt, Germany). 1.5 107 human peripheral blood
T cells were transfected with 2mM of p53 siRNA or of scrambled siRNA (Qiagen,
Hilden, Germany) using Amaxa Human T Cell Nucleofector Kit (Lonza, Basel,
Switzerland) according to the manufacturer’s instructions. The Amaxa Nucleo-
fector program U-014 was used for transfection.
Determination of DNA damage. DNA damage was determined by
quantification of g-H2AX foci formation and by alkaline single-cell gel
electrophoresis assay (comet assay). For g-H2AX staining, cells were treated
as indicated, fixed in 3% formaldehyde and permeabilized in 90% methanol.
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Following storage at  201C overnight, cells were incubated with mouse serum to
block unspecific binding and stained with antibody directed against g-H2AX
(AlexaFluor 488-coupled, 2F3; BioLegend, Fell, Germany), or with isotype control
antibody (AlexaFluor 488-coupled; BioLegend). The amount of g-H2AX foci
formation was determined by FACS measurement. Cell aliquots were taken and
confocal microscopy was carried out to visualize Etoposide-induced g-H2AX foci
formation. Nuclei were stained with DAPI mounting medium (Dianova, Hamburg,
Germany). Comet assays were carried out as previously described.59 Briefly,
electrophoresis of cellular genomic DNA was performed under alkaline conditions
at 41C. The amount of DNA damage was measured by ‘Olive Tail Moment’.
Analysis of cellular DNA damage was carried out by fluorescence microscopy,
using a fully automated cell scanning system Metafer-4 (Metasystems, Altluheim,
Germany).
RNA isolation and quantitative real-time PCR. Total cellular RNA
was isolated using the RNeasy Mini Kit (Qiagen) according to the manufacturer’s
instructions. Reverse Transcription of RNA into cDNA was carried out by use of
the High Capacity cDNA reverse transcription kit (Applied Biosystems).
Quantitative real-time PCR was performed with an ABI Prism 7500 standard
qRT-PCR cycler (Applied Biosystems) following the incorporation of SYBR Green.
Reactions were carried out in triplicate. Relative gene expression levels were
determined by normalization to the expression level of the housekeeping gene
HPRT1. The DDCt method60 was used to calculate fold expression levels.
The following primers were used: HPRT1 (forward: 50-TGACACTGGCAAAACAAT
GCA-30, reverse: 50-GGTCCTTTTCACCAGCAAGCT-30), BBC3 (PUMA) (forward:
50-GAAGAGCAAATGAGCCAAACG-30, reverse: 50-GGAGCAACCGGCAAACG-30),
MDM2 (forward: 50-ACCTCACAGATTCCAGCTTCG-30, reverse: 50-TTTCATAG
TATAAGTGTCTTTTT-30), FAS (forward: 50-AGCTTGGTCTAGAGTGAAAA-30,
reverse: 50-GAGGCAGAATCATGAGATAT-30), BAX (forward: 50-GCTGTTG
GGCTGGATCCAAG-30, reverse: 50-TCAGCCCATCTTCTTCCAGA-30), BCL2L11
(BIM) (forward: 50-ATCCCCGCTTTTCATCTTTA-30, reverse: 50-AGGACTTG
GGGTTTGTGTTG-30), TP53 (forward: 50-TCAACAAGATGTTTTGCCAACTG -30,
reverse: 50-ATGTGCTGTGACTGCTTGTAGATG -30).
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